title: Hereditary angioedema - consequences of a new treatment paradigm in Denmark.
abstract: Experiences from a Danish patient cohort with hereditary angioedema are reported with focus on home therapy and burden of illness. Eighty patients have been prospectively followed over 11 years, having experienced a total of 7,809 attacks over 469 patient years. More than half of the patients stopped long-term prophylaxis with danazol or tranexamic acid and changed treatment regimen to on-demand treatment with C1 inhibitor concentrate or icatibant. At least 10% of the attacks remained un-treated. More than half of the patients felt that hereditary angioedema had a significant psychological impact on their lives and restricted their physical activities. By December 2012, a total of 39 patients (49%) were practicing home treatment of acute attacks. Home therapy reduced the mean number of acute hospital visits by 84% and significantly improved burden of illness items. In conclusion, home therapy has profoundly improved the lives of hereditary angioedema patients.
authors.affiliation: Department of Dermatology and Allergy Centre, Odense University Hospital, DK-5000 Odense, Denmark. anette.bygum@ouh.regionsyddanmark.dk, anette.bygum@hae.dk, anette.bygum@rsyd.dk.
authors.forename: Anette
authors.initials: A
authors.lastname: Bygum
mesh_terms: D000203:Activities of Daily Living; D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D054179:Angioedemas, Hereditary / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives; D050718:Complement C1 Inhibitor Protein / Q000008:administration & dosage; D017281:Cost of Illness; D003613:Danazol / Q000008:administration & dosage; D003718:Denmark; D003879:Dermatologic Agents / Q000008:administration & dosage*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006699:Home Care Services; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D011446:Prospective Studies; D011788:Quality of Life; D012042:Registries; D013997:Time Factors; D014148:Tranexamic Acid / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D050718:Complement C1 Inhibitor Protein; D003879:Dermatologic Agents; D014148:Tranexamic Acid; C065679:icatibant; D003613:Danazol; D001920:Bradykinin